Valneva SE (VALN) Other Non-Current Liabilities (2020 - 2026)
Valneva SE (VALN) posted Other Non-Current Liabilities of $14.4 million for Q1 2026, up 6.4% sequentially from $13.6 million in Q4 2025, and up 140.16% YoY from $6.0 million in Q1 2025.
Analysis
Valneva SE (VALN) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Valneva SE has reported Other Non-Current Liabilities for 7 years, with the latest figure at $14.4 million in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 140.16% year-over-year to $14.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.4 million (up 140.16% YoY) and the FY2025 annual result came in at $13.6 million, up 2093.5% from the prior year.
- Other Non-Current Liabilities climbed to $14.4 million in Q1 2026 per VALN's latest filing, from $13.6 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $60.7 million in Q2 2022 and troughed at $583453.1 in Q4 2024.
- A 5-year average of $15.0 million and a median of $10.4 million in 2024 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities plunged 85.2% in 2022, then soared 2226.08% in 2025.
- Over 5 years, Other Non-Current Liabilities stood at $1.4 million in 2022, then retreated by 17.87% to $1.2 million in 2023, then plunged by 49.51% to $583453.1 in 2024, then surged by 2226.08% to $13.6 million in 2025, then rose by 6.4% to $14.4 million in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $14.4 million, $13.6 million, and $12.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Valneva SE | 578.54 Mn | 437.28 Mn | 1.86 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.76 Mn |
| Mar 31, 2026 | 279,808.21 |
| Dec 31, 2025 | 286,354.70 |
| Sep 30, 2025 | 32,733.54 |
| Jun 30, 2025 | 422,220.96 |
| Mar 31, 2025 | 755,253.03 |
| Dec 31, 2024 | 49,155.39 |
| Sep 30, 2024 | 57,107.41 |
| Jun 30, 2024 | 24,768.41 |
| Mar 31, 2024 | 76,045.32 |
| Dec 31, 2023 | 84,999.25 |
| Sep 30, 2023 | 95,795.96 |
| Jun 30, 2023 | 106,714.59 |
| Mar 31, 2023 | 114,847.57 |
| Dec 31, 2022 | 1.41 Mn |
| Sep 30, 2022 | 182,497.65 |
| Jun 30, 2022 | 697,855.07 |
| Mar 31, 2022 | 76,318.96 |
| Dec 31, 2021 | 78,934.00 |
| Dec 31, 2020 | 85,844.87 |